Sanjay Chanda - 15 Mar 2024 Form 4/A Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Development Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol
ANTX
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4/A
Filing time
29 Mar 2024, 16:16:55 UTC
Date Of Original Report
18 Mar 2024
Previous filing
17 Feb 2023
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +27,500 +3741% $0.000000 28,235 15 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.